Clinical advances in the treatment of pulmonary arterial hypertension

Research output: Contribution to journalArticlepeer-review


Pulmonary arterial hypertension (PAH) is a costly disease, both financially and personally. Survival rates have improved with targeted therapies, but could probably be improved more with aggressive management of medications to achieve low-risk status. Management of these patients requires complex, expensive regimens, which are likely best managed by a multidisciplinary team in a pulmonary hypertension center.

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalJournal of Managed Care Medicine
Issue number3
StatePublished - 2019


Dive into the research topics of 'Clinical advances in the treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this